|
HS Code |
289227 |
As an accredited 2-Azabicyclo[2.2.1]Heptane-2-Carboxylic Acid, 3-(6-Bromo-1H-Benzimidazol-2-Yl)-, 1,1-Dimethylethyl Ester,(1R,3S,4S)- factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 2-Azabicyclo[2.2.1]Heptane-2-Carboxylic Acid, 3-(6-Bromo-1H-Benzimidazol-2-Yl)-, 1,1-Dimethylethyl Ester,(1R,3S,4S)- prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
In the fast-moving world of synthetic chemistry, there’s often a gap between what a molecule promises on paper and how it performs in a real lab. 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester,(1R,3S,4S)- captures my attention because anyone who’s wrangled with the quirks of modern analog design appreciates the subtle value of compounds that stack useful properties. This molecule steps into a big tradition, carrying both the rigid bicyclic framework of norbornane-like systems and the versatility of a benzimidazolyl group.
Chemists like myself—who’ve sometimes stared down a stubborn coupling reaction or watched a promising candidate fall apart in the purification stage—know that structure isn’t just academic. The core 2-azabicyclo[2.2.1]heptane backbone brings a blend of ring rigidity and conformational control. This can tune bioavailability or help a lead compound steer clear of metabolic breakdown. At the same time, the benzimidazoles keep finding their way into drug discovery for good reason. They’re celebrated for their capacity to interact with biological targets, from enzymes to receptors.
It’s tempting to scan a molecular name like this and imagine it’s just another bench reagent. In my experience, that’s a missed opportunity. The introduction of the 6-bromo substituent on the benzimidazole ring sets the compound apart from less elaborated analogs. Bromine’s size and polarizability invite applications in medicinal chemistry where electronic features change protein binding in subtle but meaningful ways. This isn’t some redundant brominated routine; it’s an intentional move, deploying bromine to invite custom transformations, open up routes for Suzuki or Buchwald-Hartwig cross-couplings, or explore how halogen bonding tweaks target fit.
I’m always wary of fads in molecular scaffolds—there are cycles in research where “privileged structures” get tossed around without much thought for the real-world burdens of scale-up or consistency. This molecule’s inclusion of a tert-butyl ester isn’t just some throwaway protecting group either. The tert-butyl moiety brings air-stable handling, smoother isolation, and a built-in handle for downstream modification, thanks to the ease of deprotection under mild acidic conditions. Labs with tight time frames, or ones dealing with air or moisture-sensitive intermediates, often find that these choices are about saving resources, not just copying a literature precedent.
People outside the lab often underestimate how much work goes into the stepwise progression toward a finished, usable molecule. This compound falls into a sweet spot. Not as commonplace as the building block amines and acids that sit on every shelf, but not a one-off oddity that grinds progress to a halt. Its stereochemistry (the specific (1R,3S,4S) twist) isn’t just for show either. Anyone frustrated by racemic mixtures and the endless challenge of separating diastereomers will see the value here. By delivering a defined configuration, it avoids the unintended consequences of biological off-target effects or inconsistent results in screening.
I've often seen colleagues struggle with analog design when a non-specific side reaction or ambiguous stereoisomer ruins an entire run. With this molecule, the defined stereochemistry directly informs biological selectivity. This gives teams downstream a baseline for SAR (structure-activity relationship) studies, or synthetic chemists a template that stands up to iterative tweaking.
This isn’t some general-purpose workhorse or commodity chemical. Where other functionalized norbornane derivatives might serve as stepping stones or quick test substrates, this compound’s design shows a deeper intent—a compound crafted to bridge the gap between exploratory synthesis and real biomedical interest. The combination of norbornane rigidity with the extended pi-system of a benzimidazole, plus halogenation, gives researchers tools to probe interactions at the molecular level with unusual detail.
There's a big difference between what someone can do with basic, unsubstituted bicyclic amines and what opens up with a uniquely substituted scaffold like this. For example, structure-based drug design groups can use the bromo position as a pivot for further functionalization, exploring a suite of derivatives without changing the core of the system. That's not the kind of versatility you get from a plain norbornane or even from a simple benzimidazole.
It's easy to talk about "modularity" and "tunability" in modern chemistry, but until you've watched a carefully designed scaffold hold up under pressure—heated reactions, stringent extractions, tricky purifications—you don’t get the respect it deserves. The fusion of ring strain and aromatic extension in this compound means it doesn’t wilt under typical conditions, so the chemist using it can push reactions further without sending yield out the window. That's not a given, not even among the so-called designer intermediates flooding the catalogs right now.
Enough academic language floats around in product listings to glaze over the hard reasoning for why one version of a molecule matters more than another. This one delivers a balance of synthetic accessibility and real potential for downstream application, without demanding a PhD in analytical chemistry to handle or validate it. For those of us keeping an eye on cost, stability, and clear experimental progress rather than chasing incremental yields, that difference is real.
Many researchers I know care about actual performance, not hypothetical value. Reliable weights, no glassware etching, crystalline product that doesn’t smear across filter paper—those matter every bit as much as computational predictions. This molecule shows its worth by delivering on those expectations. The tert-butyl ester brings better shelf-life versus the methyl or ethyl variants, and the bromine offers flexibility that chlorine can't match for subsequent reactions. It slots into standard protection-deprotection workflows without excessive manipulation. Anyone who's spent a weekend battling sticky oils and mysterious byproducts can tell you that counts for a lot.
There's a constant tension between cutting costs and maintaining experimental integrity. Knock-off intermediates or impure analogs set off a cascade of troubleshooting and wasted runs. Access to a high-purity, single-isomer version of an advanced intermediate puts research efforts ahead right from the start, saving headaches months down the line. This compound stands apart from generic azabicyclo acids or simple benzimidazole derivatives. It’s not just another reagent to cycle through—it’s a meaningful stepping stone for fields like CNS ligand design, advanced materials exploration, and even photophysical studies owing to the influence of heavy atom substitutions like bromine.
I've watched enough collaborations between synthetic chemists and pharmacologists to know that the less time people spend wrestling with unpredictable impurity profiles or ambiguous stereochemistry, the more they can focus on legitimate scientific questions. Products that carry well-documented structural attributes—chirality, point of aggregation, scope for tailored modification—empower teams to correlate structure to function, whether exploring new enzyme inhibitors or adapting scaffolds for receptor mapping.
The world doesn't need another forgettable intermediate. Research groups want a molecule that can anchor a campaign: building block for new analog libraries, launching point for cross-coupling, or fragment for bioconjugation. Both the rigid azabicyclo core and benzimidazolyl system here invite creative exploration, whether someone wants to build on established bioactive frameworks or test new ground. That platform effect only works when the starting material itself can be trusted and tracked across rounds of transformation.
Looking outside the narrow confines of academic research, it’s clear that actual projects depend on compounds like this for momentum, not hypothetical appeal. Pharmaceutical startups, small biotech groups, and even advanced materials labs run into the same familiar bottleneck: absence of reliable, versatile intermediates that bridge early promise and workable application. Across years of hands-on research, the most successful projects I’ve seen are the ones that lean on a handful of well-characterized construction points that researchers know will behave as expected. This compound fits that role.
There’s a reason you won’t see this precise configuration used as a blunt tool. Instead, advanced intermediates like this serve as quiet engines for SAR exploration, fragment-based screening, or as key points in the assembly of larger, more tailored scaffolds. Its design avoids pointless complexity by focusing synthesis on the ring system most worth preserving, extending modification options through both the brominated site and the ester handle.
People sometimes lose sight of the fact that trustworthy science begins at the bench with careful choices about materials. My background includes years spent deciphering what went wrong in failed reactions, and almost always it traces back to some overlooked variable in starting material. Purity, defined stereochemistry, and functional group availability aren’t abstract perks—they’re what separates reproducible results from a dead-end lab notebook.
With this compound, both academic and industry groups have a launching pad that won’t sabotage downstream steps with hidden isomers or persistent side-products. The tert-butyl ester simplifies post-reaction isolation and delivers flexibility for subsequent synthetic plan shifts.
Designing molecules, especially for pharmaceutical or advanced material use, involves a practical sense for bottlenecks. It’s easy to reach for whatever’s available, but in my own work I've seen just how often that turns an efficient plan into a parade of workarounds. The tightly controlled geometry of this scaffold means planned modifications don't come with the risk of generating unwanted diastereomers. Its chain of functionality—acid, aromatic, and halogen—lines up with ease of further functionalization, crucial for quick pivots in med-chem or structure-guided research.
I’ve talked with researchers who spend weeks chasing a lead only to learn that the parent compound reacts unpredictably under the next condition. By starting with a well-defined structure like this, they avoid retracing old steps or hunting for alternate materials mid-campaign. In a climate where both time and funding draw sharp limits, making the right choice early matters.
Google has underscored the value of experience and evidence in evaluating claims, and I’ve long believed that the same principle holds for chemical supply choices. Anyone investing in a multi-step synthesis or competitive screening effort needs the confidence that comes from detailed documentation and reproducible supply. Suppliers who offer full characterization—NMR, HPLC, chiral purity, even stability data—aren't just ticking off regulatory boxes. They’re empowering researchers to troubleshoot faster, publish more confidently, and draw meaningful correlations from the day’s work.
It’s a small thing, but in practice, data transparency around a compound like this often tips the balance between an idea that reaches publication and one that fizzles out in the “almost worked” file. Reliable molecules accelerate innovation, and I have no doubt that scientific progress follows with better foundational materials.
Modern research lives or dies by its ability to test new ideas quickly, rigorously, and with full confidence in the tools at hand. The careful structure of 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethylethyl ester,(1R,3S,4S)- doesn’t just represent a neat bit of chemical engineering—it anchors a culture where reliable experimentation takes center stage. Instead of retracing old steps or second-guessing baseline materials, scientists can step forward, try bold ideas, and trust their results will hold up under scrutiny.
From my own perspective, there’s real satisfaction in knowing the products I work with every day uphold a standard of transparency and rigor. Small advances become possible when the basics run smoothly. The ability to customize, adapt, and redirect synthetic routes comes from a foundation that’s solid and consistent. Compounds like this play a quiet role, but their impact ripples outward, encouraging smarter projects and ultimately accelerating the pace of discovery for everyone involved.